文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

ABCB1与CES1基因多态性对房颤患者达比加群药代与药效的影响

The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation.
PubMed 文献 · Br J Clin Pharmacol · 2020-12-10

该前瞻性研究纳入198例接受达比加群治疗的非瓣膜性房颤患者,探讨ABCB1与CES1基因多态性对达比加群药代动力学、药效学及出血风险的影响。结果显示CES1 rs8192935次要等位基因C与谷浓度及谷值APTT升高相关,CES1 rs2244613次要等位基因A与谷浓度升高及轻微出血风险增加相关,而ABCB1 rs4148738和rs1045642未见显著关联。

要点

  • CES1 rs8192935次要等位基因C与达比加群谷浓度及谷值APTT升高相关。
  • CES1 rs2244613次要等位基因A与谷浓度升高及轻微出血风险增加相关。
  • ABCB1 rs4148738和rs1045642与达比加群药代/药效无显著关联。

核心结论

  • CES1 rs8192935次要等位基因C与达比加群谷浓度及谷值APTT相关。
  • CES1 rs2244613次要等位基因A与谷浓度升高及轻微出血风险增加相关。

研究设计与样本

  • 前瞻性研究,纳入198例接受达比加群治疗的非瓣膜性房颤患者。
  • 采集血样进行基因分型、血浆达比加群浓度及凝血参数测定。
  • 记录 demographics 及随访临床结局,统计分析基因多态性对PK/PD及出血风险的影响。

主要发现

  • ABCB1 rs4148738和rs1045642与达比加群PK/PD无显著关联。
  • CES1 rs8192935次要等位基因C与谷浓度升高相关(ANOVA P < .001;CC vs. TT P < .001;CT vs. TT P = .014)。
  • CES1 rs8192935次要等位基因C与谷值APTT相关(P = .015)。
  • CES1 rs2244613次要等位基因A携带者谷浓度高于非携带者(ANOVA P < .001;AA vs. CC P < .001;CA vs. CC P = .004)。
  • CES1 rs2244613次要等位基因A携带者轻微出血风险增加(P = .034;OR = 2.71,95%CI 1.05-7.00)。

临床怎么用

  • 对接受达比加群治疗的NVAF患者,可关注CES1 rs8192935和rs2244613基因型以评估谷浓度及轻微出血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Our study aimed to determine the impact of genetic polymorphisms of ABCB1 and CES1 on the pharmacokinetics (PK) and pharmacodynamics (PD) of dabigatran in patients with nonvalvular atrial fibrillation (NVAF). METHODS: We conducted a prospective study and enrolled NVAF patients treated with dabigatran. Blood samples were obtained from each patient and used for genotyping and determination of plasma dabigatran concentration (PDC) and coagulation parameters including activated partial thromboplastin time (APTT) and thrombin time. Patients' demographics and clinical outcomes from scheduled follow-up visits were all recorded. Statistical analysis was performed to identify the impact of genetic polymorphisms on the PK/PD and bleeding risk of dabigatran. RESULTS: A total of 198 patients were included in analysis. For the ABCB1 polymorphisms rs4148738 and rs1045642, no significant association was found with dabigatran PK/PD. For the CES1 polymorphism rs8192935, the minor allele(C) was associated with increased trough PDCs (ANOVA: P < .001; CC vs. TT genotype, P < .001; CT vs. TT genotype, P = .014) and with APTT values at trough level (P = .015). For the CES1 polymorphism rs2244613, the minor allele(A) carriers had higher levels of trough PDC than noncarriers (ANOVA: P < .001; AA vs. CC genotype, P < .001; CA vs. CC genotype, P = .004) and increased risk for minor bleeding (P = .034; odds ratio = 2.71, 95% confidence interval 1.05-7.00). CONCLUSION: Our study indicated that the minor allele(C) on the CES1 SNP rs8192935 was associated with PDCs and APTT values at trough level. The minor allele(A) on the CES1 SNP rs2244613 was associated with increased trough PDCs and higher risk for minor bleeding in NVAF patients treated with dabigatran.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ji Q, Zhang C, Xu Q, et al. The impact of ABCB1 and CES1 polymorphisms on dabigatran pharmacokinetics and pharmacodynamics in patients with atrial fibrillation. Br J Clin Pharmacol. 2020. PMID: 33179295. doi:10.1111/bcp.14646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。